Evaluate Efficacy and Safety of Patients with Oligometastatic NSCLC Harboring EGFR-Unmutated Treated with Stereotactic Body Radiation Therapy

Xiaolong Hu, Hongqi Li, Xiangsheng Xu, Hefei Liu, Tingyi Xia, Jianchun Zhang and Yingjie Wang

Department of Radiation Oncology, Beijing Geriatric Hospital, ChinaDepartment of Radiation Oncology, Air Force General Hospital, China

^*Correspondance to: Yingjie Wang 

 PDF  Full Text Research Article | Open Access

Abstract:

Objectives: To investigate the efficacy and adverse effects of high-dose radiotherapy to the chest primary site and all metastases sites in EGFR-unmutated Oligometastatic NSCLC patients. Methods: Retrospective analysis of 40 cases of EGFR-unmutated Oligometastatic NSCLC patients. (Metastatic lesions ≤ 5) who were initial treated by our department from 2009 to 2016. All patients underwent SBRT to the primary site and all metastases sites. Median BED10: 102.7 Gy (range: 94.5- 113.5), median chemotherapy period: 4 cycle. Kaplan-Meier survival analysis, Cox model multifactor prognosis analysis. Results: The Overall Survival (OS) of 1, 2, and 3 years is 100%, 75%, and 65.63%, respectively. The median OS was 42 months (range: 34.27-49.73M). The Progress Free Survival (PFS) of 1, 2, and 3 years are 65.00%, 10.00%, and 0%, respectively. The median PFS: was 13 months (range: 10.687-15.313 M). Multivariate analysis suggested that ECOG<2 and ECOG ≥ 2 (P=0.002) were associated with OS, BED10<100 Gy and ≥ 100 Gy (P=0.015) were associated with OS; BED10<100 Gy and ≥ 100 Gy (P=0.047) were associated with PFS. 90% of patients experienced grade 1-2 adverse reactions, no grade 3 or more side effects and treatment-related deaths. Conclusion: The EGFR-unmutated Oligometastatic NSCLC patients receiving systemic chemotherapy, combined with high-dose radiotherapy to primary site and all metastases sites can significantly improve OS and PFS. The patient has a slight adverse reaction.

Keywords:

EGFR-unmutated; Oligometastatic NSCLC; SBRT; BED10; High-dose radiotherapy

Cite the Article:

Hu X, Li H, Xu X, Liu H, Xia T, Zhang J, et al. Evaluate Efficacy and Safety of Patients with Oligometastatic NSCLC Harboring EGFR-Unmutated Treated with Stereotactic Body Radiation Therapy. Clin Oncol. 2019; 4: 1639 .